WELCOME TO
aUREALIS NEWS
READ OUR
LATEST PUBLICATION:
Aurealis Therapeutics Strengthens Its Board of Directors by Appointing Jean de Gunzburg as a New Member
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, announced today that Jean de Gunzburg, Scientist and Investor, Founder and Chairman of Zagdanut Ltd, Director of Cardiawave SA, previously CSO and Director of Da Volterra, and Founder and Chairman of Metsya Ltd, has been appointed as a new member of the company’s Board of Directors, effective June 14, 2023.
ALL PUBLICATIONS
Aurealis Therapeutics Accelerates Oncology Program: First abstract published at ASCO as the team prepares for Annual Meeting in Chicago
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has […]
Read MoreAurealis Therapeutics announces approval of multi-center, randomized, placebo-controlled diabetic foot ulcer Phase 2 study to start May 2023 in Italy, Germany and Poland.
Aurealis Therapeutics, a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene therapies, announces clinical trial application (CTA) approval of a multi-center, randomized, placebo-controlled diabetic foot ulcer (DFU) Phase 2 study to start this month in Italy, Germany, and Poland. The Global Coordinating Investigator of […]
Read MoreAurealis Therapeutics will be presenting during the European Wound Management Association (EWMA) 2023 Conference
Aurealis Therapeutics is excited to sponsor the European Wound Management Association (EWMA) 2023 Conference taking place in Milan, Italy from 3-5 May 2023. Our CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake and will be attending the conference. We will actively participate several parts of the event: On the 4th of May, Laurent Décory, COO […]
Read MoreAurealis Therapeutics is attending the Swiss Biotech Day 2023
Juha Yrjänheikki (CEO) and Laurent Décory (COO) will be attending the Swiss Biotech Day 2023 which will take place from 24-25 April in Basel, Switzerland. This will be a fantastic opportunity to meet investors and discuss potential partnerships with pharma companies. The Swiss Biotech Day is one of the leading biotechnology conferences in Europe offering […]
Read MoreAurealis Therapeutics Raises $10 Million in an Oversubscribed Series A Financing to Accelerate Phase 2 Clinical Studies in Chronic Wounds and Preclinical Development in Oncology with Its First-in-Class Technology Platform
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish Industry Investment Ltd) with participation of Huahai Pharmaceuticals, family offices and biotech HNWIs. The funds will be primarily used to […]
Read More